CEREVEL THERAPEUTICS
Unraveling the Mysteries of the Brain
Cerevel is working to unravel the mysteries of the brain and bring forward new treatment options for people living with some of the most devastating neuroscience diseases.

- Cerevel is a purpose-built company with a team of seasoned leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with expertise in clinical design and execution.

- Headquartered in Cambridge, MA, Cerevel is developing a portfolio of potential CNS therapies licensed from Pfizer and enriching the pipeline with a vibrant early discovery portfolio.

- Cerevel is focused on the development of novel therapies, combining deep understanding of neurocircuitry, with receptor subtype selectivity and differentiated pharmacology.

- Cerevel is led by a strong management team that brings to the organization a combined track record of more than 20 prior drug approvals and launches.

- Since its founding in 2018, Cerevel has delivered 2 successful data readouts, initiated 10 clinical trials, filed 5 INDs, and raised over $1 billion in capital through private financings, a go-public transaction, public offerings, and non-dilutive financing.
CEREPAL IS BUILDING OUT ITS NEUROSCIENCE EXPERTISE ACROSS THE CONTINUUM OF DRUG DISCOVERY AND DEVELOPMENT

- Chemistry
- Pharmacology
- Translational Medicine
- Clinical Trial Execution
- Regulatory Know-How
- Budding Commercial Presence

Our mission is to become the premier neuroscience company as we seek to push boundaries, develop solutions and transform lives.
Our Differentiated Approach to Treating Neuroscience Diseases

**Targeted Neurocircuitry**
Cerevel unlocks new treatment opportunities by precisely identifying and targeting the neurocircuitry that underlies a given neuroscience disease.

**Receptor Subtype Selectivity**
Cerevel is selectively targeting only the receptor subtype(s) related to the disease physiology, to minimize undesirable off-target effects while maximizing activity.

**Differentiated Pharmacology**
Cerevel designs full and partial agonists, antagonists, and allosteric modulators that can precisely fine-tune the receptor pharmacology and neurocircuit activity without over-activation or over-suppression of the endogenous physiologic range.
<table>
<thead>
<tr>
<th>Compound</th>
<th>Mechanism of Action</th>
<th>Disease Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tavapadon</td>
<td>D1/D5 Partial Agonist</td>
<td>Early and Late Parkinson’s Disease</td>
</tr>
<tr>
<td>Darigabat</td>
<td>GABA&lt;sub&gt;a&lt;/sub&gt; PAM</td>
<td>Epilepsy and Panic Disorder</td>
</tr>
<tr>
<td>Emraclidine</td>
<td>M4 PAM</td>
<td>Schizophrenia and Alzheimer’s Disease Psychosis</td>
</tr>
<tr>
<td>CVL-871</td>
<td>D1/D5 Partial Agonist</td>
<td>Dementia-related Apathy</td>
</tr>
<tr>
<td>CVL-354</td>
<td>KOR Antagonist</td>
<td>Major Depressive Disorder and Substance Use Disorder</td>
</tr>
<tr>
<td>CVL-047</td>
<td>PDE4 Inhibitor</td>
<td>Major Depressive Disorder and Schizophrenia</td>
</tr>
<tr>
<td>Candidate Selection</td>
<td>M4 Agonist</td>
<td>Schizophrenia and Psychosis in Dementia</td>
</tr>
<tr>
<td>Candidate Selection</td>
<td>LRRK2 Inhibitor</td>
<td>Parkinson’s Disease</td>
</tr>
</tbody>
</table>

Several undisclosed mechanisms, including some with disease-modifying potential

**TAVAPADON**
Partial agonist selectively targeting the dopamine D1/D5 receptor with the goal of enhancing motor control and improving tolerability compared to standard of care

**EMRACLIDINE**
Selectively targeting the M4 muscarinic receptor with the goal of effectively treating psychosis-related symptoms and improving tolerability compared to standard of care

**DARIGABAT**
Selectively targeting specific subunits of the GABA<sub>a</sub> receptor with the goal of providing anticonvulsant and anxiolytic activity with enhanced tolerability and potential for reduced abuse liability
Partnering with Cerevel
Together we can make a difference in the lives of those facing some of the most devastating neuroscience diseases

Areas of Focus
Cerevel is interested in collaborative partnerships related to novel mechanisms of action with strong genetic links to neuroscience disease pathophysiology, independent of modality. We are also actively scouting for cutting-edge technologies that advance the drug discovery process and increase the probability of clinical success.

We are open to licensing, joint ventures, research collaborations and platform technologies, from biotechnology and pharmaceutical companies, academic institutions, consortiums, and government agencies.

Our targets are rooted in causal human biology with consideration of translational biomarkers predictive of treatment response and disease outcome. The right target, the right pharmacology, the right modality for the right patient population.

Therapeutic Areas of Interest

MOVEMENT DISORDERS
- Parkinson’s Disease
- Amyotrophic Lateral Sclerosis
- Huntington’s Disease

Schizophrenia
Anxiety Disorders
Depression
Bipolar Disorder
Cognitive Disorders

NEUROPSYCHIATRY

NEUROLOGY
- Epilepsy
- Multiple Sclerosis
- Developmental and Epileptic Encephalopathy
- Pain

Dementia-related
- Apathy
- Alzheimer’s Disease
- Psychosis

DEMENTIA
- Lewy Body Dementia

- Parkinson’s Disease
- Amyotrophic Lateral Sclerosis
- Huntington’s Disease

- Schizophrenia
- Anxiety Disorders
- Depression
- Bipolar Disorder
- Cognitive Disorders

- Epilepsy
- Multiple Sclerosis
- Developmental and Epileptic Encephalopathy
- Pain

- Dementia-related
- Apathy
- Alzheimer’s Disease
- Psychosis

- Lewy Body Dementia

- Parkinson’s Disease
- Amyotrophic Lateral Sclerosis
- Huntington’s Disease

- Schizophrenia
- Anxiety Disorders
- Depression
- Bipolar Disorder
- Cognitive Disorders

- Epilepsy
- Multiple Sclerosis
- Developmental and Epileptic Encephalopathy
- Pain

- Dementia-related
- Apathy
- Alzheimer’s Disease
- Psychosis

- Lewy Body Dementia
Avenues of Innovation

- AI/ML augmented applications to identify new targets and perform multi-parameter optimization of small molecules
- Imaging tools for target engagement and compound effects
- Novel approaches to treat neuroscience diseases such as small molecule RNA modulators
- Novel target identification and screening technologies
- Ex vivo and in vivo models predictive of disease
- Innovative translational biomarkers approaches that are predictive of disease progression, treatment response, and patient stratification
- Protein degrader platforms for neuroscience targets
- Brain delivery technology to enhance the passage of therapeutics across the blood brain barrier
Interested in working with us?

Contact us at partnering@cerevel.com